Exhibit 99.1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a statement on Schedule 13G (including amendments thereto) with respect to the common shares, par value $0.001, of Revance Therapeutics, Inc., and further agrees that this joint filing agreement be included as an exhibit to such filings.
Dated: February 17, 2015
NovaQuest Pharma Opportunities Fund III, L.P. | |||
By: NQ HCIF General Partner, L.P., its General Partner | |||
By: | NQ HCIF GP, Ltd., its General Partner | ||
By: | /s/ John L. Bradley, Jr. | ||
Name: John L. Bradley, Jr. | |||
Title: Director |
NQ HCIF General Partner, L.P. | ||||
By: | NQ HCIF GP, Ltd., its General Partner | |||
By: | /s/ John L. Bradley, Jr. | |||
Name: John L. Bradley, Jr. | ||||
Title: Director |
NQ HCIF GP, Ltd. | |||
By: | /s/ John L. Bradley, Jr. | ||
Name: John L. Bradley, Jr. | |||
Title: Director |